摘要
目的:本研究旨在初步探讨氟维司群在治疗男性乳腺癌的临床疗效。方法:回顾分析了我院乳腺外科术后接受氟维司群治疗的3例男性乳腺癌患者的临床资料。结果:3例患者经氟维司群治疗均有效,1例截止随访时间2013年3月仍存活,2例死亡。3例患者中2例应用氟维司群出现不良反应(乏力、潮热、瘙痒)。3例患者中2例ER、PR表达呈阳性,1例呈阴性,ER、PR阳性者在TTP、OS上要优于ER、PR阴性者。结论:氟维司群可以作为治疗以ER高表达为主要特征的男性乳腺癌的新型内分泌治疗手段,安全性高且耐受性好。
Objective：To preliminarily explore the clinical efficacy of fulvestrant in the treatment of male breast cancer. Methods：Retrospective analysis of clinical data of 3 male breast cancer patients treated with fulvestrant in our hospital after breast surgery. Results：Fulvestrant treatment was effective on all cases and by the follow-up time to March 2013, 1 case still alive, 2 cases of death. Two of three patients with fulvestrant appeared adverse reactions （including fatigue, hot flashes, itching）. 2 cases were positive for ER and PR expression but 1 case negative, the cases of ER and PR positive on the TTP, OS is superior to the case of negative. Conclusion：Fulvestrant is effective in the treatment of male breast cancer with endocrine therapy, and is better tolerated. The reactivity is especially better to high ER expression in fulvestrant.
出处
《中国医药导刊》
2014年第4期691-691,693,共2页
Chinese Journal of Medicinal Guide
